Su-Hsin Chang1, Suhong Luo1, Theodore S Thomas1, Katiuscia K O'Brian1, Graham A Colditz1, Nils P Carlsson1, Kenneth R Carson1. 1. Affiliations of authors: Research Service, St. Louis Veterans Affairs Medical Center, St. Louis, MO (SHC, SL, TST, KKO, KRC); Division of Public Health Sciences, Department of Surgery (SHC, GAC, NPC, KRC), and Division of Oncology, Department of Internal Medicine (SL, KKO, KRC), Washington University School of Medicine, St. Louis, MO.
Abstract
Background: Multiple myeloma (MM) is one of the most common hematologic malignancies in the United States and is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS). This study investigates the role of obesity in the progression of MGUS to MM. Methods: A retrospective identified cohort of patients in the US Veterans Health Administration database diagnosed with MGUS between October 1, 1999, and December 31, 2009, was followed through August 6, 2013. Patient-level clinical data were reviewed to verify MM diagnosis, if any. Survival analyses utilizing interval-censored data were used to investigate the risk of progression of MGUS to MM. Statistical tests were two-sided. Results: The analytic cohort consisted of 7878 MGUS patients with a median follow-up of 68 months. Within the cohort, 39.8% were overweight and 33.8% were obese; 64.1% were of white race. During follow-up, 329 MGUS patients (4.2%) progressed to MM: 72 (3.5%) normal-weight patients (median follow-up = 61.9 months), 144 (4.6%) overweight patients (median follow-up = 69.1 months), and 113 (4.3%) obese patients (median follow-up = 70.6 months). In the multivariable analysis, overweight (hazard ratio [HR] = 1.55, 95% confidence interval [CI] = 1.16 to 2.06) and obesity (HR = 1.98, 95% CI = 1.47 to 2.68) were associated with an increased risk of transformation of MGUS to MM. Moreover, black race was associated with a higher risk of MM (HR = 1.98, 95% CI = 1.55 to 2.54). Conclusions: Obesity and black race are risk factors for transformation of MGUS to MM. Future clinical trials should examine whether weight loss is a way to prevent the progression to MM in MGUS patients.
Background: Multiple myeloma (MM) is one of the most common hematologic malignancies in the United States and is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS). This study investigates the role of obesity in the progression of MGUS to MM. Methods: A retrospective identified cohort of patients in the US Veterans Health Administration database diagnosed with MGUS between October 1, 1999, and December 31, 2009, was followed through August 6, 2013. Patient-level clinical data were reviewed to verify MM diagnosis, if any. Survival analyses utilizing interval-censored data were used to investigate the risk of progression of MGUS to MM. Statistical tests were two-sided. Results: The analytic cohort consisted of 7878 MGUS patients with a median follow-up of 68 months. Within the cohort, 39.8% were overweight and 33.8% were obese; 64.1% were of white race. During follow-up, 329 MGUS patients (4.2%) progressed to MM: 72 (3.5%) normal-weight patients (median follow-up = 61.9 months), 144 (4.6%) overweight patients (median follow-up = 69.1 months), and 113 (4.3%) obesepatients (median follow-up = 70.6 months). In the multivariable analysis, overweight (hazard ratio [HR] = 1.55, 95% confidence interval [CI] = 1.16 to 2.06) and obesity (HR = 1.98, 95% CI = 1.47 to 2.68) were associated with an increased risk of transformation of MGUS to MM. Moreover, black race was associated with a higher risk of MM (HR = 1.98, 95% CI = 1.55 to 2.54). Conclusions: Obesity and black race are risk factors for transformation of MGUS to MM. Future clinical trials should examine whether weight loss is a way to prevent the progression to MM in MGUS patients.
Authors: Ola Landgren; Gloria Gridley; Ingemar Turesson; Neil E Caporaso; Lynn R Goldin; Dalsu Baris; Thomas R Fears; Robert N Hoover; Martha S Linet Journal: Blood Date: 2005-10-06 Impact factor: 22.113
Authors: Dominik D Alexander; Pamela J Mink; Hans-Olov Adami; Philip Cole; Jack S Mandel; Martin M Oken; Dimitrios Trichopoulos Journal: Int J Cancer Date: 2007 Impact factor: 7.396
Authors: Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar Journal: Blood Date: 2009-01-29 Impact factor: 22.113
Authors: Ernesto Pérez-Persona; María-Belén Vidriales; Gema Mateo; Ramón García-Sanz; Maria-Victoria Mateos; Alfonso García de Coca; Josefina Galende; Guillermo Martín-Nuñez; José M Alonso; Natalia de Las Heras; José M Hernández; Alejandro Martín; Consuelo López-Berges; Alberto Orfao; Jesús F San Miguel Journal: Blood Date: 2007-06-18 Impact factor: 22.113
Authors: Jonathan N Hofmann; Linda M Liao; Michael N Pollak; Ye Wang; Ruth M Pfeiffer; Dalsu Baris; Gabriella Andreotti; Qing Lan; Ola Landgren; Nathaniel Rothman; Mark P Purdue Journal: Blood Date: 2012-09-24 Impact factor: 22.113
Authors: Erica M Bullwinkle; Melissa D Parker; Nicole F Bonan; Lauren G Falkenberg; Steven P Davison; Kathleen L DeCicco-Skinner Journal: Cancer Lett Date: 2016-06-16 Impact factor: 8.679
Authors: Kylee Maclachlan; Benjamin Diamond; Francesco Maura; Jens Hillengass; Ingemar Turesson; C Ola Landgren; Dickran Kazandjian Journal: Best Pract Res Clin Haematol Date: 2020-01-11 Impact factor: 3.020
Authors: Molly Went; Alex J Cornish; Philip J Law; Ben Kinnersley; Mark van Duin; Niels Weinhold; Asta Försti; Markus Hansson; Pieter Sonneveld; Hartmut Goldschmidt; Gareth J Morgan; Kari Hemminki; Björn Nilsson; Martin Kaiser; Richard S Houlston Journal: Blood Adv Date: 2020-05-26
Authors: Geffen Kleinstern; Dirk R Larson; Cristine Allmer; Aaron D Norman; Grace Muntifering; Jason Sinnwell; Alissa Visram; Vincent Rajkumar; Angela Dispenzieri; Robert A Kyle; Susan L Slager; Shaji Kumar; Celine M Vachon Journal: Blood Cancer J Date: 2022-04-19 Impact factor: 9.812
Authors: Su-Hsin Chang; Jason Gumbel; Suhong Luo; Theodore S Thomas; Kristen M Sanfilippo; Jingqin Luo; Graham A Colditz; Kenneth R Carson Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-09-09 Impact factor: 4.254
Authors: Catherine R Marinac; Brenda M Birmann; I-Min Lee; Bernard A Rosner; Mary K Townsend; Edward Giovannucci; Timothy R Rebbeck; Julie E Buring; Graham A Colditz Journal: Br J Cancer Date: 2018-03-12 Impact factor: 7.640
Authors: Catherine R Marinac; Catherine A Suppan; Edward Giovannucci; Mingyang Song; Ane S Kværner; Mary K Townsend; Bernard A Rosner; Timothy R Rebbeck; Graham A Colditz; Brenda M Birmann Journal: JNCI Cancer Spectr Date: 2019-06-24